FDA tasks Congress with tightening diagnostics regulation
Loosely regulated diagnostics are leading to improper patient care and burgeoning medical costs, FDA and CMS are arguing to Congress - which is why they want to tighten up approval processes.
Loosely regulated diagnostics are leading to improper patient care and burgeoning medical costs, FDA and CMS are arguing to Congress - which is why they want to tighten up approval processes.
In her speech at Advamed 2013, FDA Commissioner Dr. Margaret Hamburg said a new challenge will be regulating in some way lab development tests. Now, LDTs are left to CLIA, which, Hamburg said, does not ensure they are properly designed, consistently assembled or clinically valid. She called for a “critical baseline” of these sorts of in […]
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.